ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

AstraZeneca and Daiichi Sankyo reported that ENHERTU achieved a statistically significant and clinically meaningful progression-free-survival benefit over platinum-pemetrexed chemotherapy plus pembrolizumab in the Phase III DESTINY-Lung04 trial. The study supports ENHERTU’s potential use as a first-line therapy for patients with unresectable locally advanced or metastatic HER2-mutant non-squamous non-small-cell lung cancer, representing a potentially meaningful commercial and clinical expansion opportunity.

Analysis

The economic value is not simply a new patient cohort: moving ENHERTU earlier in the treatment pathway should lengthen treated duration and reduce attrition before second-line therapy. HER2-mutant disease is a low-single-digit share of non-squamous NSCLC, so this is unlikely to alter AZN's consolidated earnings trajectory alone; it is, however, a more material de-risking event for Daiichi Sankyo (4568 JP) and for the broader antibody-drug conjugate platform valuation.

The key near-term debate is whether the PFS result converts into a commercially differentiated label rather than a niche biomarker indication. Overall-survival maturity, depth/durability of response, and interstitial-lung-disease discontinuation rates will determine physician adoption against a familiar chemo-immunotherapy regimen. A safety trade-off that requires intensive monitoring would cap first-line penetration even with a statistically positive trial, while a clean OS trend could make this a guideline-driven testing catalyst within 6-12 months.

Consensus may overstate the immediate AZN read-through because ENHERTU economics are shared and AZN's portfolio is large; the more investable second-order effect is validation of HER2 testing at diagnosis and of DXd payloads in frontline lung cancer. That supports molecular-diagnostic utilization at Guardant Health (GH) and Exact Sciences (EXAS), but only if guideline language mandates broad next-generation sequencing rather than merely recommends it. The principal falsifier is detailed safety/OS data that imply PFS is achieved at an unacceptable treatment-burden cost.

Key Decisions for Investors

• Maintain or add a modest AZN long on weakness over the next 1-3 months, but treat this as a pipeline-risk reducer rather than a standalone earnings trade; reassess at full data presentation. A material OS deficit, elevated grade 3+ toxicity, or ILD-driven discontinuation above prior ENHERTU experience invalidates the thesis.
• Prefer long Daiichi Sankyo (4568 JP) versus AZN as the higher-beta expression over 6-12 months, subject to liquidity and currency constraints. The pair captures greater sensitivity to incremental ENHERTU duration and platform validation; exit if regulator-facing data show weak OS support or restrictive pulmonary-safety language.
• Put GH and EXAS on a 6-18 month watchlist rather than initiating solely on this result. Upgrade only if NCCN or equivalent guidelines explicitly strengthen upfront comprehensive genomic testing, or if management reports lung-test volume acceleration; absent that evidence, the diagnostic revenue read-through is too indirect.